Importantly, blockade of FXYD6 by our self-generated anti-FXYD6 functional antibody significantly inhibited xenografted tumor growth, suggesting that FXYD6 is a novel therapeutic target toward HCC. The gene discussed is FXYD6; the disease is hepatocellular carcinoma.